Novo Nordisk CagriSema Linked to 25% Weight Loss in Women
Novo said the experimental injection also reduced abdominal fat, with a separate analysis showing 26.7% weight loss in premenopausal women.
- On Tuesday, Novo Nordisk announced two post hoc analyses of its REDEFINE 1 trial, showing investigational drug CagriSema was associated with 25% average weight loss among adult women at 68 weeks.
- CagriSema, a combination of semaglutide and the amylin analog cagrilintide, addresses weight gain during menopause when hormonal shifts increase abdominal fat accumulation.
- The analyses showed weight loss reached 26.7% for premenopausal, 24.8% for perimenopausal, and 23.1% for postmenopausal women, with waist circumference falling 20.5 cm versus 4.7 cm on placebo.
- Novo Nordisk described the analyses as hypothesis-generating; Dr. Maria Hurtado Andrade of Mayo Clinic Alix School of Medicine said further research is needed to understand reproductive aging effects on weight loss.
- A decision on CagriSema approval is expected in the fourth quarter of this year, following the New Drug Application Novo Nordisk filed with the U.S. Food and Drug Administration in December 2025.
10 Articles
10 Articles
Danish pharmaceutical company Novo Nordisk published the results of analyzing the weight loss effects of women before and after menopause who participated in clinical phase 3 of 'Cagrisema', a candidate for next-generation obesity treatment. Novo (Novo) revealed on the 20th (local time) that the 68-week average weight loss rate of the cagrisema administration group was 25% as a result of post-analysis of data from 2309 women who participated in …
Novo’s CagriSema helped women lose 25% of weight on average, analysis shows - Regional Media News
Oct 20 (Reuters) - Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on average in women with obesity or overweight, according to data analyzed after the completion of a late-stage study. CagriSema, viewed as a successor to the Danish [...]
Novo Nordisk's latest analysis shows that the company's next-generation obesity drug, CagriSema, resulted in an average of 25 percent weight loss in adult women in a post-hoc analysis of data from a phase III clinical trial, CNBC reported.
Novo's CagriSema was associated with 25% weight loss on average for women in a post hoc analysis of REDEFINE 1 presented at The Menopause Society Annual Meeting
Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc...
Coverage Details
Bias Distribution
- 57% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
